OOIR: Observatory of International Research

Papers

(The median citation count of Current Opinion in Rheumatology is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)

Article	Citations
Recent advances in immunometabolism in rheumatic diseases	59
A cursed goodbye kiss from severe acute respiratory syndrome-coronavirus-2 to its pediatric hosts: multisystem inflammatory syndrome in children	48
Autoantibodies in rheumatoid arthritis – rheumatoid factor, anticitrullinated protein antibodies and beyond	45
Nonsteroidal anti-inflammatory drugs and cardiovascular disease risk in spondyloarthritis-spectrum diseases	45
Is severe COVID-19 a cytokine storm syndrome: a hyperinflammatory debate	39
Uveitis in Behçet disease - an update	35
The impact of dietary interventions in psoriatic arthritis	35
Metabolic perturbations in systemic sclerosis	35
Educational needs and challenges in axial spondyloarthritis	34
Integrating genetic and social factors to understand health disparities in lupus	33
Complications of severe acute respiratory syndrome coronavirus 2 infection in children	30
Quo vadis reactive arthritis?	29
Type 1 interferon activation in systemic sclerosis: a biomarker, a target or the culprit	24
Tocilizumab in giant cell arteritis: an update for the clinician	23
Editorial introduction	21
Is it time to move on from pelvic radiography as the first-line imaging modality for suspected sacroiliitis?	20
Epidemiology of systemic vasculitis	20
Chimeric antigen receptor T-cell therapy in rheumatology: B-cell depletion 2.0	19
Imaging in pediatric spondyloarthritis	19
Go or no-go for treat-to-target in axial spondyloarthritis?	19
An update on topical therapies for psoriasis	18
Novel therapies in juvenile idiopathic arthritis	18
Persistent hand pain despite adequate immunosuppression? The distinct value of occupational therapy in the era of biologics	18
What is PFAPA syndrome? Genetic clues about the pathogenesis	17
Not all benign: disease course, complications, and sequalae of chronic recurrent multifocal osteomyelitis in children	16

Current views on lupus in children	16
Contribution of keratinocytes to dermal fibrosis	15
Neurovascular dysregulation in systemic sclerosis: novel insights into pathophysiology, diagnosis, and treatment utilizing invasive cardiopulmonary exercise testing	14
Urticarial vasculitis	14
Autologous hematopoietic stem cell transplant for systemic sclerosis associated interstitial lung disease	14
Current approach to muscle imaging in myositis	14
Polymyalgia rheumatica and giant cell arteritis: diagnosis and management	14
Giant cell arteritis: update on pathogenesis and clinical implications	14
Update on antineutrophil cytoplasmic autoantibody vasculitis in children	13
Blood and urine biomarkers in osteoarthritis – an update on cartilage associated type II collagen and aggrecan markers	13
Epidemiology of systemic vasculitis	12
A treat-to-target approach is needed for Behçet's syndrome	12
Polymyositis: does it really exist as a distinct clinical subset?	12
Optimizing reproductive health management in lupus and Sjogren's syndrome	12
Review of publications evaluating opioid use in patients with inflammatory rheumatic disease	12
New developments related to lung complications in pediatric rheumatic disease	11
When to stop medication in juvenile idiopathic arthritis	11
Editorial introductions	11
Recent findings in idiopathic inflammatory myopathies with potential diagnostic and therapeutic implications	11
The impact of the COVID-19 pandemic on the field of pediatric rheumatology	11
Medium-vessel and large-vessel vasculitis in children	11
Rheumatologic immune checkpoint inhibitor-related adverse events	11
The role of immunomodulatory medications in the treatment of COVID-19	10
The safety of glucocorticoids in the treatment of inflammatory rheumatic disease: new evidence	10
Editorial introduction	10
Transcriptomics data: pointing the way to subclassification and personalized medicine in systemic lupus erythematosus	9
Osteoporosis epidemiology using international cohorts	9
Editorial introductions	9
Diagnostic delay in axial spondyloarthritis – a past or current problem?	9
The dynamic organelle primary cilia: emerging roles in organ fibrosis	9
Inflammatory back pain: a concept, not a diagnosis	9
Update on treatment responses and outcome measure development in chronic nonbacterial osteomyelitis	8
Twenty years of clinical trials in axial spondyloarthritis: what can we learn for the future?	8
Telerheumatology: before, during, and after a global pandemic	8
New molecular targets in the treatment of rheumatoid arthritis	8
Navigating the complexity of pain in psoriatic arthritis and axial spondyloarthritis	8
Editorial introductions	8
Novel imaging techniques for sacroiliac joint assessment	7
Juvenile Behçet syndrome: a contemporary view and differential diagnosis in pediatric practice	7
Systemic sclerosis: beyond skin and lung involvement	7
The complement system in antineutrophil cytoplasmic antibody-associated vasculitis: pathogenic player and therapeutic target	7
Axial spondyloarthritis guidelines – aiming for maximum impact	7
Insights into origins and specificities of autoantibodies in systemic sclerosis	7
Calcinosis in dermatomyositis	7
Out of the shadow of interleukin-17A: the role of interleukin-17F and other interleukin-17 family cytokines in spondyloarthritis	7
Renal disease in pediatric rheumatology	7
Insights into the molecular landscape of osteoarthritis in human tissues	7
Diagnosis and management of primary heart involvement in systemic sclerosis	7
Dual-energy computed tomography in crystalline arthritis: knowns and unknowns	7
Editorial introductions	7

Scleroderma autoantibodies in guiding monitoring and treatment decisions	7
Low-dose computed tomography for axial spondyloarthritis: update on use and limitations	6
Chimeric antigen receptors: “CARs” in the fast lane for rheumatology	6
Rheumatoid arthritis – the challenge of heterogeneity	6
Impact of rheumatoid arthritis and biologic and targeted synthetic disease modifying antirheumatic agents on cancer risk and recurrence	6
Glucocorticoid-induced osteoporosis in premenopausal women: management for the rheumatologist	6
Interstitial lung disease throughout the rheumatoid arthritis disease course	6
Sodium-glucose cotransporter 2 inhibitors: are they ready for prime time in the management of lupus nephritis?	6
2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria sets for three types of antineutrophilic cytoplasmic antibody-associated vasculitis	6
The association of Behçet's syndrome with HLA-B51 as understood in 2021	6
Antiphospholipid syndrome management: a 2023 update and practical algorithm-based approach	6
How can ultrasonography help in the management of CPPD? From diagnosis to clinical subset identification	6
Anti-MDA5 dermatomyositis: an update from bench to bedside	6
Vasculitis and the NLRP3 inflammasome	5
Glucocorticoid and opioid use in rheumatoid arthritis management	5
Healthcare disparities in telemedicine for rheumatology care	5
Skeletal muscle immunohistochemistry of acquired and hereditary myopathies	5
Targeting B cells for treatment of systemic sclerosis	5
Practical management of Raynaud's phenomenon – a primer for practicing physicians	5
Advances in understanding and examining lymphatic function: relevance for understanding autoimmunity	5
Low-dose interleukin-2 therapy: a promising targeted therapeutic approach for systemic lupus erythematosus	5
Recent advances in the use of machine learning and artificial intelligence to improve diagnosis, predict flares, and enrich clinical trials in lupus	5
Coronavirus disease 2019: update on coronavirus disease 2019 outcomes and vaccine efficacy in patients with immune-mediated inflammatory disease	5
Editorial introduction	5
Editorial introductions	5
Calcinosis in systemic sclerosis	4
Management of postinfectious inflammatory arthritis	4
Investigating gout flares: beyond a definition	4
Editorial introduction	4
Composite measures to assess disease damage, disease severity and treatment response in systemic sclerosis clinical trials	4
Lymphocyte immunophenotyping in inflammatory myositis: a review	4
Cluster analysis as a clinical and research tool in Behçet's syndrome	4
Microbiome dynamics in rheumatic diseases	4
Emerging biologic therapies for systemic lupus erythematosus	3
Recent advances on neutrophil dysregulation in the pathogenesis of rheumatic diseases	3
Omics studies in Behçet's disease	3
Genetic and epigenetic factors shape phenotypes and outcomes in systemic lupus erythematosus – focus on juvenile-onset systemic lupus erythematosus	3
Exploring challenges in the management and treatment of inclusion body myositis	3
Epidemiology of osteoarthritis: literature update 2022–2023	3
Current efforts and historical perspectives on classification of idiopathic inflammatory myopathies	3
Gastrointestinal involvement in systemic sclerosis: pathogenesis, assessment and treatment	3
From traditional to targeted: the changing trajectory of therapies in dermatomyositis	3
Janus kinase inhibitors: efficacy and safety	3
Heart involvement in systemic sclerosis: emerging concepts	3
Autoantibody testing in myositis: an update	3
Inclusion body myositis: an update	3
Editorial introductions	2
Environmental triggers for connective tissue disease: the case of COVID-19 associated with dermatomyositis-specific autoantibodies	2
50 years of spondyloarthritis: a look back and a look ahead	2
Differential diagnosis of necrotizing myopathy	2
Adipose tissue and adipose secretome in systemic sclerosis	2
The role of PET/CT in disease activity assessment in patients with large vessel vasculitis	2
MicroRNAs in idiopathic inflammatory myopathies: state-of-the-art and future perspectives	2
Updates on translational and clinical research in systemic sclerosis	2
Cryoglobulinemic vasculitis: a 2023 update	2
Cardiovascular disease in spondyloarthritis: a narrative review of risk factors and the effect of treatments	2
Editorial: Introduction, Vasculitis 2021	2
Safety of biologic agents for the management of rheumatic diseases during pregnancy	2
Biomarkers of disease activity in dermatomyositis	2
Clinical features of multisystem inflammatory syndrome in children	2
Animal models in systemic sclerosis: an update	2
Fibromyalgia and centralized pain in the rheumatoid arthritis patient	2
Acute and postacute COVID-19 outcomes for patients with rheumatoid arthritis: lessons learned and emerging directions 3 years into the pandemic	2
Janus kinase–signal transducers and activators of transcription cell signaling in Spondyloarthritis: rationale and evidence for JAK inhibition	2
Disease modification in axial spondyloarthritis – still a controversy?	2
Current management of giant cell arteritis and its complications	2
Cardiovascular complications of rheumatoid arthritis	2
Current treatment approach to ANCA-associated vasculitis	2
Editorial introduction	2
Editorial introduction	2
Myopathy in systemic sclerosis	2
Updates on interstitial lung disease and other selected extra-articular manifestations of rheumatoid arthritis	2